Canada has a long history of global leadership on regenerative medicine and diabetes treatments, as both stem cells and insulin were discovered by Canadian researchers. The federal government builds on this legacy by supporting the technology development and manufacturing of next generation bioprinted tissue therapeutics with applications for diabetes and other serious health conditions including liver disease. This support will strengthen Canada’s position as a global leader in a new wave of therapeutic innovations and medicines.